AX-2024-005044

LL-37 · 10 mg declared · Shanghai Sigma-Audley New Material Technology Co., Ltd. · lot SSA-2403-V6369

PASSIDENTITY CONSISTENT

Report ID: AX-2024-005044
Compound: LL-37
Compound class: Tissue-repair and immunomodulatory peptides
Supplier: SSA — Shanghai Sigma-Audley New Material Technology Co., Ltd.
Batch / lot: SSA-2403-V6369
Declared label claim: 10mg
Laboratory: VendorInvestigate
Assay date: 28 May 2024
Submitted: 29 May 2024
Quarter: 2024-Q2
Submitter: ru.kirchner
Sample provenance: Laboratory-retained

Section 1

Results

Measured against the index acceptance specification for the tissue-repair and immunomodulatory peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 32 min gradient, 214 nm	98.12	% area	≥ 96.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	1.88	% area	≤ 3.5	PASS
Largest single impurity	RP-HPLC — truncated (1-31)	1.10	% area	≤ 1.00	FAIL
Identity — theoretical monoisotopic mass	calculated from molecular formula	4490.4265	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	4490.4175	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-2.0	ppm	± 15	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	2.23	%	≤ 10.0	PASS
Counter-ion (TFA)	anion-exchange ion chromatography	9.86	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.42	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White powder, no defined cake (melt-back)	—	white to off-white intact cake	FAIL
Reconstitution clarity	reconstituted per submitter procedure	Faint haze, clearing on standing	—	clear, no visible particulates	FAIL
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	3.23	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 32 min gradient	15.29	min	15.24 ± 0.40 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.22	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	36,312	—	≥ 20,000	PASS
Resolution to nearest impurity	vs deamidated (+1 Da)	0.84	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 32 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 36,312, and skew follows the reported asymmetry factor of 1.22. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 1.10 % impurity against a 98.12 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	LL-37 — main peak	15.29	4,768,936	98.12	—
2	truncated (1-31)	13.50	53,463	1.10	-709.401
3	aggregated multimer	18.33	20,899	0.43	0.000
4	des-Leu1 (−113 Da)	14.88	8,263	0.17	-113.084
5	deamidated (+1 Da)	15.01	5,832	0.12	+0.984
6	trifluoroacetyl adduct (+96 Da)	16.19	2,916	0.06	+95.982
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 4490.4265 Da, computed from C205H340N60O53. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 4490.4175 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
6+	749.4117	749.4102	-0.0015	8.5
5+	899.0926	899.0908	-0.0018	55.3
4+	1123.6139	1123.6117	-0.0022	100.0
3+	1497.8161	1497.8131	-0.0030	54.5

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.12	98.12	divergence -0.04 pp vs batch median
Total impurities (% area)	1.88	1.88
Largest single impurity (% area)	not stated	1.10
Water (%)	1.5	2.23
Counter-ion (%)	not stated	9.86
Peptide content (%w/w)	93.7	not determined
Endotoxin (EU/mg)	0.24	not determined
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Laboratory-retained
Evidentiary weight: Provenance documented, selection uncontrolled.
Chain of custody: Laboratory retained sample (−20 °C, 21 d since original receipt) → re-assay.
Assay date: 28 May 2024
Submitted to the index: 29 May 2024
Laboratory: VendorInvestigate, Riga, Latvia
Method basis: 32 min gradient · high-resolution MS
Verification status: IDENTITY CONSISTENT

What this report does not establish

How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 1

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

quad_unit29 May 2024

Instrument class is on the record, which is what allows -2.0 ppm to be read at its proper weight. The index distinguishes "confirmed" from "consistent with" precisely on this field.

Section 7

Related records

Same batch — lot SSA-2403-V6369 n=4

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2024-005042	SSA-2403-V6369	PeptideMeter	2024-Q2	98.07	1.83	91.7	Buyer-sourced	PASS
AX-2024-005043	SSA-2403-V6369	VendorInvestigate	2024-Q2	98.19	2.35	98.3	Buyer-sourced	PASS
AX-2024-005045	SSA-2403-V6369	Janoshik	2024-Q2	98.51	2.50	107.1	Buyer-sourced	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent LL-37 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042473	Homopeptide	HOMO-2602-G5165	Janoshik	2026-Q3	99.01	5.00	—	Buyer-sourced	0	PASS
AX-2026-042474	Homopeptide	HOMO-2602-G5165	Janoshik	2026-Q3	99.18	5.44	—	Buyer-sourced	0	PASS
AX-2026-042472	Homopeptide	HOMO-2602-G5165	Nordanalyt	2026-Q3	98.75	5.17	—	Buyer-sourced	0	PASS
AX-2025-019154	SinoPep	SNP-2411-X3762	Janoshik	2025-Q1	98.65	2.63	—	Buyer-sourced	1	MARGINAL
AX-2025-019153	SinoPep	SNP-2411-X3762	Janoshik	2025-Q1	99.38	2.17	91.6	Buyer-sourced	1	MARGINAL
AX-2025-019155	SinoPep	SNP-2411-X3762	Janoshik	2025-Q1	99.63	3.28	94.1	Buyer-sourced	1	MARGINAL
AX-2025-019159	SinoPep	SNP-2411-X3762	Nordanalyt	2025-Q1	98.90	2.77	96.0	Buyer-sourced	1	MARGINAL
AX-2025-019160	SinoPep	SNP-2411-X3762	Medutest	2025-Q1	99.30	2.73	102.0	Laboratory-retained	1	MARGINAL

Other recent SSA records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043135	BPC-157	SSA-2601-N6863	Nordanalyt	2026-Q2	98.16	4.66	92.8	Buyer-sourced	1	MARGINAL
AX-2026-043160	GHK-Cu	SSA-2604-V7731	Janoshik	2026-Q2	98.01	4.02	91.8	Buyer-sourced	0	PASS
AX-2026-043157	GHK-Cu	SSA-2604-V7731	Medutest	2026-Q2	99.19	5.14	—	Supplier-supplied	0	PASS
AX-2026-043141	BPC-157	SSA-2601-N6863	Janoshik	2026-Q2	98.06	4.06	94.6	Buyer-sourced	1	MARGINAL
AX-2026-043154	GHK-Cu	SSA-2604-V7731	PeptideMeter	2026-Q2	97.82	4.82	101.6	Buyer-sourced	0	PASS
AX-2026-043137	BPC-157	SSA-2601-N6863	PeptideMeter	2026-Q2	98.17	4.14	—	Buyer-sourced	1	MARGINAL
AX-2026-043162	GHK-Cu	SSA-2604-V7731	Janoshik	2026-Q2	98.50	4.36	—	Supplier-supplied	0	PASS
AX-2026-043134	BPC-157	SSA-2601-N6863	Medutest	2026-Q2	97.89	4.01	—	Buyer-sourced	1	FAIL